Last updated: February 19, 2026
Case Overview: Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc. (1:17-cv-00374-LPS)
This litigation centers on Bristol-Myers Squibb Company's (BMS) blockbuster drug, Eliquis (apixaban), a direct oral anticoagulant. BMS alleges that Aurobindo Pharma USA Inc. infringes upon several of its key patents covering apixaban and its use. The core of the dispute involves Aurobindo's Abbreviated New Drug Application (ANDA) seeking to market a generic version of Eliquis. This analysis outlines the patent landscape, the litigation's progression, key arguments, and potential implications for both companies and the broader anticoagulant market.
What Patents Are at Issue?
The litigation involves several United States patents held by BMS, primarily related to apixaban. These patents cover various aspects of the drug, including its chemical composition, methods of synthesis, and therapeutic uses. The asserted patents in this specific litigation include:
- U.S. Patent No. 7,399,757: This patent claims the compound apixaban. It is a foundational patent for the drug.
- U.S. Patent No. 8,557,800: This patent claims methods of treating thrombotic disorders using apixaban.
- U.S. Patent No. 8,735,378: This patent also claims methods of treating thrombotic disorders using apixaban.
- U.S. Patent No. 9,034,917: This patent claims methods of manufacturing apixaban.
(Source: Court Filings, Case No. 1:17-cv-00374-LPS)
What Are the Core Allegations?
BMS alleges that Aurobindo's proposed generic apixaban product and its manufacturing processes infringe upon the asserted BMS patents. Specifically, BMS claims that Aurobindo's ANDA for generic apixaban infringes Claims 1, 4, 6, 10, 13, and 15 of U.S. Patent No. 7,399,757; Claims 1, 4, 5, 6, 7, 8, and 11 of U.S. Patent No. 8,557,800; Claims 1, 5, 6, 7, 8, and 11 of U.S. Patent No. 8,735,378; and Claims 1, 2, 3, 4, 5, and 7 of U.S. Patent No. 9,034,917. BMS seeks injunctive relief to prevent Aurobindo from launching its generic product until the expiration of the asserted patents.
(Source: Complaint, Case No. 1:17-cv-00374-LPS)
What Are Aurobindo's Defenses?
Aurobindo, like most generic manufacturers in Paragraph IV litigation, challenges the validity and enforceability of BMS's asserted patents. Aurobindo's primary defenses typically include:
- Non-infringement: Aurobindo argues that its proposed generic product does not infringe the claims of BMS's patents. This often involves demonstrating that their product or manufacturing process operates outside the scope of the patent claims.
- Invalidity: Aurobindo challenges the validity of the asserted patents, arguing they are not patentable subject matter, lack novelty, or would have been obvious to a person of ordinary skill in the art at the time of invention. This can involve citing prior art that predates BMS's patent filings.
- Unenforceability: Aurobindo may also argue that the patents are unenforceable due to issues such as inequitable conduct before the United States Patent and Trademark Office (USPTO) or patent misuse.
(Source: Answer to Complaint, Case No. 1:17-cv-00374-LPS)
How Has the Litigation Progressed?
The litigation was initiated by BMS filing a complaint against Aurobindo on March 30, 2017. The case was assigned to Judge Gregory M. Sleet initially and later transferred to Judge Liam O’Scannlain and then to Chief Judge Christopher J. Burke. Subsequently, the case was reassigned to Chief Judge Maryellen Noreika. The proceedings have followed a typical Hatch-Waxman litigation track, involving:
- Filing of Complaint: BMS initiates the lawsuit alleging patent infringement.
- Filing of Answer: Aurobindo responds with its defenses.
- Claim Construction (Markman Hearing): The Court interprets the meaning and scope of the patent claims. This is a critical phase as claim interpretation directly impacts infringement and validity analyses.
- Discovery: Parties exchange information, including documents and depositions.
- Summary Judgment Motions: Parties may file motions seeking judgment on certain issues without a full trial.
- Trial: If not resolved by summary judgment or settlement, the case proceeds to trial.
- Appeals: Parties can appeal the court's decisions to the United States Court of Appeals for the Federal Circuit.
Significant developments in this case have included claim construction proceedings. In this specific litigation, the court has issued rulings on claim construction. For instance, in its Markman order dated March 16, 2021, the Court construed various terms within the asserted patents.
(Source: Court Orders, Case No. 1:17-cv-00374-LPS)
What Were the Key Claim Construction Rulings?
Claim construction is pivotal in patent litigation, as it defines the boundaries of the asserted patent rights. The Court's interpretations of key terms in the asserted patents directly influence the infringement and validity analyses. For example, in its March 16, 2021 Markman Order, the Court construed several terms, including those related to the chemical structure of apixaban and the administration of the drug. These constructions are critical for determining whether Aurobindo's proposed generic product falls within the scope of BMS's patent claims.
(Source: Markman Order, Case No. 1:17-cv-00374-LPS)
What is the Status of the Litigation?
As of recent filings, the litigation has seen significant activity, including summary judgment motions and potential settlement discussions. The parties have filed various motions, including motions for summary judgment of non-infringement and/or invalidity. The Court has issued orders addressing these motions. The specific outcome of these motions and any subsequent appeals or settlements will determine the final resolution of this patent dispute.
(Source: Docket Entries, Case No. 1:17-cv-00374-LPS)
What Are the Market Implications?
The outcome of this litigation has substantial implications for both BMS and the generic pharmaceutical market.
- For Bristol-Myers Squibb: A favorable outcome for BMS would mean continued market exclusivity for Eliquis, protecting its significant revenue stream. Eliquis is a major contributor to BMS's overall sales, with global revenues in the billions of dollars annually. Blocking generic entry maintains this financial advantage.
- For Aurobindo Pharma: A favorable outcome for Aurobindo would permit the launch of its generic apixaban product, allowing it to capture a share of the lucrative anticoagulant market. Generic entry typically leads to significant price reductions for the drug, increasing patient access and competition.
- For the Market: The resolution of this case will influence the competitive landscape of the anticoagulant market. Generic entry for a drug as widely prescribed as apixaban would likely lead to substantial cost savings for healthcare systems and patients. The timing of generic entry is directly tied to the strength and duration of patent protection.
Eliquis (apixaban) competes in a market with other anticoagulants, including warfarin, direct thrombin inhibitors, and other direct oral anticoagulants (DOACs) like rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). The introduction of generic apixaban would intensify competition among DOACs.
Key Takeaways
- Bristol-Myers Squibb's U.S. Patent Nos. 7,399,757, 8,557,800, 8,735,378, and 9,034,917 are central to the dispute over generic apixaban.
- BMS alleges Aurobindo's ANDA for generic apixaban infringes these patents, seeking to prevent market entry.
- Aurobindo defends by challenging the validity and asserting non-infringement of the asserted patents.
- Claim construction rulings by the court have been critical in defining the scope of BMS's patent rights.
- The litigation's resolution will significantly impact Eliquis's market exclusivity and the competitive dynamics of the anticoagulant market.
Frequently Asked Questions
What is the significance of Paragraph IV in this litigation?
Paragraph IV of the Hatch-Waxman Act allows a generic drug applicant to certify to the FDA that its proposed drug does not infringe any patent listed in the Orange Book, or that the listed patent is invalid or unenforceable. Filing under Paragraph IV triggers patent litigation initiated by the brand-name drug manufacturer, as seen in this case.
How does claim construction impact the litigation's outcome?
Claim construction, often determined through a Markman hearing, defines the meaning and scope of patent claims. Broad claim constructions favor the patent holder by encompassing more potential infringing products and processes. Narrower constructions favor the generic challenger by limiting the patent's reach.
What are the typical timelines for Hatch-Waxman litigation?
Hatch-Waxman litigation can be lengthy, often taking several years from the filing of an ANDA to a final court decision. This timeline includes claim construction, discovery, potential summary judgment motions, and trial, followed by potential appeals.
What is the commercial importance of Eliquis (apixaban)?
Eliquis is a blockbuster drug for Bristol-Myers Squibb, generating tens of billions of dollars in annual revenue. Its significant sales underscore the high stakes for both BMS in defending its patent exclusivity and for generic manufacturers seeking to enter this profitable market.
What are the potential financial consequences of losing this litigation for Aurobindo?
If Aurobindo loses, it will be enjoined from launching its generic apixaban product until the expiration of BMS's asserted patents. This means a significant delay in market entry and a loss of potential revenue. Conversely, if Aurobindo wins, it can launch its generic product, potentially gaining a substantial market share and generating significant revenue, while also driving down the drug's price.
Citations
[1] United States District Court for the District of Delaware. (2017). Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc., Case No. 1:17-cv-00374-LPS. Complaint.
[2] United States District Court for the District of Delaware. (2017). Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc., Case No. 1:17-cv-00374-LPS. Answer to Complaint.
[3] United States District Court for the District of Delaware. (2021). Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc., Case No. 1:17-cv-00374-LPS. Markman Order.
[4] United States District Court for the District of Delaware. (2017-Present). Bristol-Myers Squibb Company v. Aurobindo Pharma USA Inc., Case No. 1:17-cv-00374-LPS. Docket Entries.
